Modulating immune cell behavior in solid tumors
Targeting Tregs in the solid tumor microenvironment by modulating metabolite signaling
['FUNDING_R21'] · FRED HUTCHINSON CANCER CENTER · NIH-10973890
This study is looking at how certain substances in tumors affect immune cells that can help or hinder the body's fight against cancer, with the goal of finding better ways to boost cancer treatments for patients.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10973890 on ClinicalTrials.gov |
What this research studies
This research investigates how certain metabolites in the tumor microenvironment affect immune cells, particularly regulatory T cells (Tregs), which can suppress the body's immune response against tumors. By understanding how these metabolites, like succinate, influence Tregs, the research aims to develop strategies to enhance the effectiveness of immunotherapies for solid tumors. The approach involves targeting the signaling pathways activated by these metabolites to improve the infiltration and function of CD8+ T cells, which are crucial for attacking cancer cells. Patients may benefit from new treatment options that could lead to better outcomes in cancer therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with solid tumors who are undergoing or considering immunotherapy.
Not a fit: Patients with non-solid tumors or those who do not qualify for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for patients with solid tumors.
How similar studies have performed: Other research has shown promise in targeting metabolic pathways in the tumor microenvironment to enhance immunotherapy effectiveness, indicating a potential for success in this approach.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KINSELLA, SINÉAD — FRED HUTCHINSON CANCER CENTER
- Study coordinator: KINSELLA, SINÉAD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.